---
title: "Amylyx Pharmaceuticals Inc (AMLX) Gets a Buy from LifeSci Capital"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296687342.md"
description: "LifeSci Capital analyst Rami Katkhuda maintained a Buy rating on Amylyx Pharmaceuticals (AMLX) with a $44 price target. This follows H.C. Wainwright's August 20 report, which also reiterated a Buy rating and set a higher $55 price target for the stock."
datetime: "2026-08-22T19:35:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296687342.md)
  - [en](https://longbridge.com/en/news/296687342.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296687342.md)
generator: "portal-rs"
---

# Amylyx Pharmaceuticals Inc (AMLX) Gets a Buy from LifeSci Capital

LifeSci Capital analyst Rami Katkhuda maintained a Buy rating on Amylyx Pharmaceuticals Inc today and set a price target of $44.00.

### Summer Sale - Claim 70% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Katkhuda covers the Healthcare sector, focusing on stocks such as Eledon Pharmaceuticals, Disc Medicine, and Vera Therapeutics. According to TipRanks, Katkhuda has an average return of 34.4% and a 56.32% success rate on recommended stocks. 

In a report released on August 20, H.C. Wainwright also reiterated a Buy rating on the stock with a $55.00 price target.

### Related Stocks

- [AMLX.US](https://longbridge.com/en/quote/AMLX.US.md)
- [ELDN.US](https://longbridge.com/en/quote/ELDN.US.md)
- [IRON.US](https://longbridge.com/en/quote/IRON.US.md)
- [VERA.US](https://longbridge.com/en/quote/VERA.US.md)

## Related News & Research

- [39,241 Shares in Amylyx Pharmaceuticals, Inc. $AMLX Bought by GSA Capital Partners LLP](https://longbridge.com/en/news/296452266.md)
- [Amylyx Pharmaceuticals Inc (AMLX) Receives a Buy from Guggenheim](https://longbridge.com/en/news/285935233.md)
- [Canaccord Genuity Reaffirms Their Buy Rating on ACADIA Pharmaceuticals (ACAD)](https://longbridge.com/en/news/297902410.md)
- [RBC Capital Keeps Their Buy Rating on Cytokinetics (CYTK)](https://longbridge.com/en/news/297724700.md)
- [Clinuvel Pharmaceuticals  (CLVLF) was downgraded to a Hold Rating at Morgans](https://longbridge.com/en/news/297444018.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**